Vector BioMed Launches in Maryland with Gene Therapy Industry Veteran at Helm to Address the Vector Supply Bottleneck with End-to-End Solutions Platform

Published on : Published by : Chris Frew

Biomanufacturing Company Vector BioMed Launches with Mission to Provide Access to High-Quality Lentiviral Vectors and Address the Vector Supply Bottleneck
NEWS PROVIDED BY
Vector BioMed
Jan 31, 2023, 07:30 ET
SHARE THIS ARTICLE
First Round Funding Led by Viking Global Investors and Casdin Capital
Boro Dropulić, Ph.D., MBA, named Chief Executive Officer of Vector BioMed
GAITHERSBURG, Md., Jan. 31, 2023 /PRNewswire/ — Vector BioMed, a biomanufacturing company specializing in the manufacture of lentiviral vectors, today announced its launch and first financing round led by Viking Global Investors and Casdin Capital. The funds will support the acceleration of commercial operations to provide rapid access to high-quality lentiviral vectors for pre-clinical development, clinical trials, and commercialization.
In contrast to traditional contract development and manufacturing organizations (CDMOs), Vector BioMed is a solution provider that will provide partners with the capabilities to take their lentiviral vector-based medicinal concepts into the clinic and accelerate their path to commercialization. Vector BioMed will help address the industry’s current vector supply bottleneck by providing lentiviral vectors at scale, while also offering turnkey solutions for vector design and optimization, pre-clinical manufacturing, GMP manufacturing, and other support services.
In conjunction with the funding and launch, co-founder Boro Dropulić, Ph.D., MBA has…

Gene Editing with CRISPR

Published on : Published by : Chris Frew

This rigorous three day program is ideal for basic research and translational biology scientists who are looking for a balanced theoretical vs. hands-on introduction to CRISPR toolkit. Directed by Dr. [….]

Histochemical Society Immunohistochemistry & Immunofluorescence Workshop

Published on : Published by : BioBuzz Media

This 4.5-day laboratory short course is ideal for experimental and translational research scientists, diagnosticians, and technical staff who are new to immunohistochemistry and immunofluorescence or those with experience who aim [….]

Gene Editing with CRISPR

Published on : Published by : BioBuzz Media

This rigorous three day program is ideal for basic research and translational biology scientists who are looking for a balanced theoretical vs. hands-on introduction to CRISPR toolkit. Directed by Dr. [….]

Gene Editing with CRISPR/Cas9: Advanced Topics

Published on : Published by : BioBuzz Media

Advanced Gene Editing with CRISPR is a 3-day hands-on workshop designed for researchers with entry level experience in CRISPR/Cas9 technology seeking a more in-depth immersion in state-of-art CRISPR applications such [….]

Five Philly Gene Therapy Companies You Should Know

Published on : Published by : Bryan Spiegelberg, Ph.D.

More than 40 cell and gene therapy companies call Philadelphia home. Their work is facilitated by academic/industrial partnerships with world-class scientists at Children’s Hospital of Philadelphia (CHOP), Temple University, Drexel University, and University of Pennsylvania. Led by Wilson, UPenn’s Gene Therapy Program has been a particularly strong catalyst of the growth that led to $3 billion in investment in cell and gene therapies (CGT) in 2021. 

Global Cell and Gene Therapy Company Miltenyi Biotec is Expanding its Operations in Maryland 

Published on : Published by : BioBuzz Media

BALTIMORE, MD (March 15, 2022) — Global biotechnology business Miltenyi Biotec is expanding its operations in Maryland and transferring its North American headquarters to Gaithersburg. The company is working on expanding its 1201 Clopper Road facility to support additional manufacturing, research and development, quality assurance, and more. Miltenyi Biotec plans to add 130 new full-time jobs in Maryland, giving it a total of 300 employees in the state by the end of the year.
“By selecting Maryland for its North American headquarters, Miltenyi Biotec will help us continue growing our industry and further our efforts in remaining one of the top 10 life sciences clusters in the nation,” said Governor Larry Hogan. “We welcome the company’s continued investment in Montgomery County and look forward to supporting their efforts in Maryland and across the globe.”
This is not the company’s first investment in Maryland in recent years. In 2014, Miltenyi Biotec acquired Gaithersburg’s lentiviral vector manufacturing company Lentigen Technology Inc., which develops and commercializes therapeutics for stem cell therapies and oncology. In 2017, the company acquired Living Pharma, Inc., a startup of the University of Maryland, Baltimore that develops personalized cell therapy for targeted individuals’ cancers and diseases. Both became part…

NF2 BioSolutions Is Accelerating Research to Cure a Rare Tumor Disease

Collage of individuals with NF2 with text saying "I Need a Cure" and NF2 BioSolutions Logo
Published on : Published by : Sarah Ellinwood

Neurofibromatosis type II, also known as NF2, is a rare disease caused by a mutation in the NF2 gene, whose protein product, “Merlin”, plays a key role in managing cell proliferation. In Merlin’s absence, cells will grow unchecked, forming benign tumors throughout the body.

American Gene Technologies says clinical trial shows increases in immunity against HIV

Published on : Published by : BioBuzz Media

ROCKVILLE, Md. (7News) — There’s more good news in the fight to cure HIV.
American Gene Technologies says its clinical trial has resulted in more patients with substantial increases in virus-specific T-cells with immunity against HIV.
Progress in HIV cure: AGT hopes to have a ‘functionally cured patient by next summer’
“Now the question will be the very final step when we withdraw antiretroviral therapy, will it behave as we expect which is to take over viral suppression and these patients will not need to go back on their antiretroviral therapy again,” said CEO Jeff Galvin.
He says that process would start by the end of March at the earliest and he hopes to find out how successful it is by June.